REVELATION BIOSCIENCES, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
REVELATION BIOSCIENCES, INC. (REVB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $782.46 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $3.41M.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.79M, a 209.15% decline year-over-year.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $2.56M, a 79.44% decline year-over-year.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $12.45M, a 110.60% increase year-over-year.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $4.20M.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$5.49M, a 181.51% decline from fiscal 2023.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $6.74M, a 69.39% increase from fiscal 2022.
- REVELATION BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $3.98M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $782.46K 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $3.41M 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $4.20M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $6.21M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | -$1.33M 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | -$2.79M 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | -$5.49M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$5.45M 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | $81.36K 10-Q · filed 2025-08-08 | ||||
| 2024-03-31 | $2.56M 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $6.74M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $8.74M 10-Q · filed 2024-11-08 | ||||
| 2023-06-30 | $10.46M 10-Q/A · filed 2024-09-23 | ||||
| 2023-03-31 | $12.45M 10-Q/A · filed 2024-09-23 | ||||
| 2022-12-31 | $3.98M 10-K/A · filed 2024-09-23 | ||||
| 2022-09-30 | $4.92M 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $2.20M 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | $5.91M 10-Q · filed 2023-05-22 | ||||
| 2021-12-31 | -$3.22M 10-K · filed 2023-03-30 | $66.80K 10-K · filed 2022-04-15 | |||
| 2021-09-30 | -$354.92K 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $1.88M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $5.52M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $11.73K 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |